For the quarter ending 2026-01-31, PMCB has $55,873,565 in assets. $16,471,229 in debts. $20,165,535 in cash and cash equivalents.
| Balance Sheets | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 20,165,535 | 15,406,017 | 13,178,305 | 15,172,163 |
| Marketable equity securities | 372,251 | 201,190 | 261,853 | 366,316 |
| Warrant asset qcls - current | 0 | 1,912,000 | 820,000 | 2,917,000 |
| Convertible note receivable femasys - current | 0 | 5,000,000 | 4,608,000 | 3,696,000 |
| Prepaid expenses and other current assets | 158,664 | 503,147 | 238,180 | 223,759 |
| Total current assets | 20,696,450 | 23,022,354 | 19,106,338 | 22,375,238 |
| Intangible asset | 1,549,427 | 1,549,427 | 1,549,427 | 1,549,427 |
| Investment in preferred stock qcls | 22,472,000 | 20,747,000 | 19,635,000 | 22,474,000 |
| Warrant asset qcls non current | 10,242,000 | 9,530,000 | 2,966,000 | 5,701,000 |
| Warrant asset femasys | 906,000 | 1,120,000 | 1,846,000 | 3,061,000 |
| Convertible note receivable femasys - non current | - | - | - | 0 |
| Other assets | 7,688 | 7,688 | 7,688 | 7,688 |
| Total other assets | 35,177,115 | 32,954,115 | 26,004,115 | 32,793,115 |
| Total assets | 55,873,565 | 55,976,469 | 45,110,453 | 55,168,353 |
| Accounts payable | 1,200,082 | 1,021,339 | 465,209 | 399,204 |
| Accrued expenses | 445,656 | 520,656 | 595,656 | 2,515,080 |
| Accrued series c dividends | 32,491 | 35,389 | - | 0 |
| Total current liabilities | 1,678,229 | 1,577,384 | 1,060,865 | 2,914,284 |
| Long-term portion of accrued expenses | 0 | 0 | 0 | 25,000 |
| Warrant liabilities | 13,657,000 | 16,152,000 | 458,000 | 338,000 |
| Derivative liabilities | 1,136,000 | 1,693,000 | - | 0 |
| Total other liabilities | 14,793,000 | 17,845,000 | 458,000 | 363,000 |
| Total liabilities | 16,471,229 | 19,422,384 | 1,518,865 | 3,277,284 |
| Convertible preferred stock-Series BPreferred Stock | 0 | 0 | 0 | 0 |
| Convertible preferred stock-Series CPreferred Stock | 872,323 | 901,996 | - | - |
| Contingently redeemable warrants | 417,000 | 417,000 | - | - |
| Total temporary equity | 1,289,323 | 1,318,996 | - | - |
| Preferred stock value | 0 | 0 | 0 | 0 |
| Common stock authorized 200,000,000 shares, 0.0001 par value 26,005,715 and 21,672,095 shares issued and 10,735,649 and 6,795,779 shares outstanding as of january 31, 2026 and april 30, 2025, respectively | 2,602 | 2,167 | 2,167 | 2,167 |
| Additional paid-in capital | 183,141,663 | 180,611,996 | 181,550,139 | 181,489,647 |
| Accumulated deficit | -100,000,171 | -100,747,031 | -93,329,056 | -84,968,960 |
| Treasury stock, at cost, 15,270,066 and 14,876,316 shares as of january 31, 2026, and april 30, 2025, respectively | 45,009,541 | 44,607,916 | 44,607,916 | 44,607,916 |
| Accumulated other comprehensive loss | -21,540 | -24,127 | -23,746 | -23,869 |
| Total stockholders equity | 38,113,013 | 35,235,089 | 43,591,588 | 51,891,069 |
| Total liabilities, temporary equity and stockholders equity | 55,873,565 | 55,976,469 | 45,110,453 | 55,168,353 |
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)